Mark Vincent
Directeur/Bestuurslid bij APTOSE BIOSCIENCES INC.
Vermogen: 502 $ op 30-04-2024
Actieve functies van Mark Vincent
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| APTOSE BIOSCIENCES INC. | Directeur/Bestuurslid | 19-09-2007 | - |
| Independent Dir/Board Member | 19-09-2007 | - | |
| Sarissa, Inc. | Directeur/Bestuurslid | 18-01-2011 | - |
| Algemeen Directeur | 01-01-2000 | - | |
| Oprichter | 01-01-2000 | - | |
| University of Western Ontario | Corporate Officer/Principal | 01-01-2008 | - |
Loopbaan van Mark Vincent
Eerdere bekende functies van Mark Vincent
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
DRI Capital, Inc.
 DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Directeur/Bestuurslid | - | - |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 01-01-2000 | - |
Opleiding van Mark Vincent
| University of Cape Town | Doctorate Degree |
Statistieken
Internationaal
| Canada | 4 |
| Verenigde Staten | 2 |
| Verenigd Koninkrijk | 2 |
Operationeel
| Director/Board Member | 3 |
| Corporate Officer/Principal | 2 |
| Chief Executive Officer | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
| Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| APTOSE BIOSCIENCES INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
DRI Capital, Inc.
DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Finance |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
| Sarissa, Inc. |
- Beurs
- Insiders
- Mark Vincent
- Ervaring
